Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial

Authors

Institutions

Publication Details

Journal
Journal for ImmunoTherapy of Cancer
Published
2024-10-01
DOI
https://doi.org/10.1136/jitc-2024-009662
Citations
8
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
2.26
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial

Meiyu Fang, Quanli Gao, Xiaolu Tao, Bixia Tang et al.
8 citations
Journal for ImmunoTherapy of Cancer
Cancer Immunotherapy and Biomarkers
2.26
article

Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial

Meiyu Fang, Quanli Gao, Xiaolu Tao, Bixia Tang, Rong Duan, Yu Jiang, Ruixuan Luo, Shuai Zhao, Michael Lee, Yu Chen, Gang Huang, Jun Guo, Xiaoshi Zhang, Meng Qi, Rongqing Li, Zhihong Chi, Fei Zheng, Yao Li, Xiubao Ren, Meijuan Gao, Feng Li, Jing Chen, Chuanliang Cui
article en
8 citations

Abstract

No abstract available for this paper.
Journal for ImmunoTherapy of CancerVol. 12(10)
Fujian Medical University (CN), Central South University (CN), Sun Yat-sen University (CN), Peking University (CN), Sichuan University (CN), Kunming Medical University (CN), Tianjin Medical University Cancer Institute and Hospital (CN), West China Hospital of Sichuan University (CN), Peking University Cancer Hospital (CN), Zhejiang Cancer Hospital (CN), Hunan Cancer Hospital (CN), First Affiliated Hospital of Kunming Medical University (CN), First Affiliated Hospital of Xi'an Jiaotong University (CN), Wuhan Union Hospital (CN), Shanghai Harbour Engineering Design & Research Institute (CN), Henan Cancer Hospital (CN), Sun Yat-sen University Cancer Center (CN), Fujian Provincial Cancer Hospital (CN)
Good health and well-being
Openalex Percentile: Top 10%
Cancer Immunotherapy and Biomarkers
2.26
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.